News
Adjuvant Treatment of Early Invasive HER2+ Breast Cancer − Results of the Katherine Study
Women with breast cancer found to have residual invasive disease during surgery after neoadjuvant chemotherapy and HER2-targeted therapy have a significantly worse prognosis. For these patients, the Czech Oncology Society ČLS JEP recommends adjuvant therapy with trastuzumab emtansine based on data from the Katherine clinical study. However, this treatment has not yet been covered by public health insurance, with reimbursement starting from March 1, 2021.
Sport as an Important Part of the Life of Hemophiliacs
People with congenital bleeding disorders have very diverse approaches to sports and exercise. The…
Turoctocog Alfa Pegol in Surgical Procedures – Experiences from Pathfinder 3 and 5 Studies
The Haemophilia journal published data in May 2020 from 2 studies that summarize experiences with…
Does Beta-Blocker Therapy Reduce the Cardiovascular Benefit of Aerobic Exercise in Patients with Arterial Hypertension?
Regular aerobic exercise is generally recommended for patients suffering from arterial hypertension…
Change in Release of Medication Pradaxa
Dear Doctor,
We would like to inform you that from April 1, 2021, based on the decision of the…
We would like to inform you that from April 1, 2021, based on the decision of the…
How does Benzalkonium Chloride and Prostaglandins Affect Meibomian Gland Epithelial Cells?
Benzalkonium chloride is commonly used in eye drops intended for glaucoma treatment due to its…
Effect of Prostaglandin Analogues With and Without Preservatives on Meibomian Glands in Glaucoma Patients
Prostaglandin analogues (PGA) have become a standard in the treatment of open-angle glaucoma.…
Post-COVID Depression: How Can a General Practitioner Help?
Psychiatrists confirm that mental health plays an increasingly important role in the context of the…
If Suicides Were COVID-19... or Why We Still Overlook a Significant Cause of Premature Deaths?
More than a year since the start of the pandemic, the SARS-CoV-2 coronavirus has claimed 2.8…
Lorlatinib showed significant benefit in 1st line treatment of advanced ALK-positive non-small cell lung carcinoma
In the international CROWN study, lorlatinib compared to crizotinib led to a 72% reduction in the…
Conferences
News from the world of medicine
All conferences
Popular this week
- Shooting at the Faculty of Arts of Charles University and activation of the trauma plan at the First Surgical Clinic of the General Teaching Hospital
- BENIGN DERMATOSIS OF PENIS
- Does AI Evaluate Patients' Health More Accurately Than Doctors?
- Brain scans of patients with multiple sclerosis will be evaluated by AI
- New method promises personalized diagnostics and more effective diabetes treatment